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2006 – 2008 Veterans Health Administration administrative data. There were 2,462
colorectal cancer patients receiving chemotherapy to estimate the effect of ESA on
mortality. Propensity score weighted Cox proportional hazard regressions were
performed. An interaction between ESAs and granulocyte colony stimulating fac-
tors (G-CSFs) was assessed. RESULTS: Overall, 12.7% of patients receiving chemo-
therapy in the cohort used ESAs at some time during the follow-up period. The
mean age of patients was 65.3 (standard deviation: 10.50) ranged from 22 to 97
years. The unadjusted Kaplan-Meier curves showed worse survival for ESA users
than non-users. There was no difference in survival between epoetin and darbe-
poetin. The estimated hazard ratio (HR) of ESA use for mortality was 2.045 (95% CI
 1.799 – 2.326) in a propensity score weighted model. The parameter estimate of
the interaction term between ESAs and G-CSFs was statistically significant
(-0.51574with standard error 0.20183, p0.0106). In the stratified analysis, the HR
was attenuated among the group of G-CSF users; HR  1.392; 95%CI  0.961, 2.017
for G-CSF users versusHR 2.327; 95%CI 2.027, 2.672 for non-users. This confirms
that there is an interaction between ESAs and G-CSFs. CONCLUSIONS: The use of
ESA was associated with decreased survival in colorectal cancer patients receiving
chemotherapy. There was no difference in the risks between ESA agents. The di-
rection of estimates was consistent with the results from the meta-analyses of
randomized clinical trials. Our study exclusively focused on colorectal cancer pa-
tients who were actively receiving chemotherapy and compared mortality rates
between ESA users and non-users in the study population. Our findings signifi-
cantly add to knowledge in oncology care in community practice.
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OBJECTIVES: Lenalidomide (LEN) and bortezomib (BORT) are effective drugs for the
treatment of refractory MM. Both agents have demonstrated an improvement in
disease response, progression free (PFS) and overall survival (OS) in the refractory
MM setting. NNT represents the number of patients that need to be treated with a
new intervention in order to have one additional patient deriving benefit, and is a
powerful approach that can be used to make sense of numerical results from clin-
ical trials. The NNT approach was used in the current study to compare LEN and
BOR in patients with relapsed MM. METHODS: The pivotal randomized trials for
LEN (Weber, Dimopoulos, 2007) and BORT (Richardson, 2005) were reviewed. A key
requirement for a NNT comparative analysis is that all outcomes be measured
against a comparable control. The NNT was then calculated for both agents with
respect to disease response and PFS at 12 months by taking the reciprocal of the
absolute differences in treatment effect between the experimental therapies and
the control group. RESULTS: For a disease response, theNNT for LEN and BORTwas
3 and 5 patients respectively; to have one additional patient achieving a disease
response. A difference in the NNT was also noted for PFS at 12 months; only 3
patients would need to be treated with LEN for an additional patient remaining
progression free compared to 9 with BORT. This is a relevant finding because it
suggests a 3 fold relative increase in clinical benefit in patients treat with LEN
compared to BORT. CONCLUSIONS: More patients treated with LEN are likely to
respond and to achieve a 12 month PFS than comparable patients treated with
BORT. Possible reasons for this effect include differences in the trial population,
extent of disease, and/or true differences in efficacy.
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OBJECTIVES: Breast cancer outcomes have improvedwith recent advancements in
diagnosis and treatment. Interest in breast cancer prevention is growing, andmore
clinical evidence is needed regarding the effects of preventive therapy, alone or in
combination, on breast cancer. METHODS: This was a nationwide case-control
analysis from the Taiwan National health Insurance Research Database. We ana-
lysed 16,847 female breast cancer cases among women older than 50 years who
were diagnosed between January 1, 2002, and December 31, 2008. A matched con-
trol group consisted of 50,460 matched subjects. Longitudinal exposure to angio-
tensin-converting enzyme (ACE) inhibitors, non-steroidal anti-inflammatory drugs
(NSAIDs), and aspirin was compared between women who had a first-time diag-
nosis of breast cancer and matched controls without a diagnosis of breast cancer.
RESULTS: The risk of breast cancer among patients taking both aspirin and ACEI
decreased as the ACEI dose increased. Among patients receiving between 28-364
cumulative defined daily doses (cDDD) of aspirin, the adjusted ORs were 0.97 (0.90-
1.06), 0.91 (0.82-1.03) and 0.79 (0.68-0.92) for women taking ACEI for 0-27, 28-364,
and 365 cDDD, respectively. Among women receiving 365 cDDD of aspirin, the
adjusted ORs were 0.91 (0.80-1.03), 0.81 (0.70-0.94) and 0.81 (0.71-0.92) as the ACEI
dose increased, respectively. Women taking non-aspirin NSAIDs along with ACEI
had the same finding. Amongwomen taking 28 - 364 cDDD of NSAIDs, the adjusted
ORs were 0.85 (0.81-0.89), 0.87 (0.81-0.94) and 0.80 (0.73-0.88) ; for women receiving
365 cDDD of NSAIDs, the adjusted ORs were 0.68 (0.62-0.74), 0.61 (0.53-0.70) and
0.60 (0.52-0.70) as the ACEI dose increased, respectively. CONCLUSIONS: The find-
ings of this nationwide case-control analysis support the hypothesis that ACE in-
hibitors enhance the antitumor effect of cyclooxygenase (COX) inhibitors on breast
cancer. There was no statistically significant association between use of any ACE
inhibitor alone and breast cancer rates.
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OBJECTIVES: Some observational studies indicate that androgen deprivation ther-
apy (ADT) for prostate cancer (PC) is associated with cardiovascular disease. How-
ever, the results are not currently identified in the Asian populations. We assessed
whether ADT is associated with cardiovascular disease, using a population-based
dataset. METHODS: This cohort study used data sourced from the Longitudinal
Health Insurance Database. A total of 693 subjects who were newly diagnosed PC
between January 1, 1998 and December 31, 2007, and followed until December 31,
2009. There were 313 subjects received ADT (GnRH agonists, oral antiandrogen, the
combination of the two, orchiectomy). Cox proportional hazardsmodels were used
to assess whether ADT was associated with coronary heart disease (CHD), stroke,
or heart failure, after adjusting for age, location, socioeconomic status, co-morbid-
ities, drug, year of diagnosis and type of procedure. RESULTS: In survival analysis,
ADT use was not associated with an increased risk of CHD (adjusted hazard ratio
[aHR]  1.08, 95% CI  0.747 to 1.557), stroke (aHR  0.97, 95% CI  0.661 to 1.414),
heart failure (aHR  1.22, 95% CI  0.791 to 1.875). GnRH agonist and combination
oral antiandrogen were both not associated with any outcomes. Low cumulative
dose (0-53 DDD) of antiandrogen was associated with significantly increased risks
of CHD (aHR  3.91, 95% CI  1.257 to 12.141). Among patients not treated with
radical prostatectomy, GnRH agonist use was associated with increased risk of
heart failure (aHR  2.32, 95% CI  1.010 to 5.324). Among patients with CHD,
combined therapy was associated with increased risk of heart failure (aHR  2.71,
95% CI 1.078 to 6.807). CONCLUSIONS: Low cumulative dose of antiandrogenwas
associated with increased risks of CHD. The use of combined therapy appears to be
associated with increased risk of heart failure in patients with CHD.
PCN9
EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM AMONG CANCER PATIENTS
IN TAIWAN
Chew TW1, Hsiao FY1, Gau CS2, Wen YW3
1National Taiwan University, Taipei, Taiwan, 2Center for Drug Evaluation, Taipei, Taiwan,
3Chang Gung University, Taoyuan, Taiwan
OBJECTIVES: Venous thromboembolism (VTE) is a common complication among
cancer patients which results in significant morbidity and mortality. Although the
need to optimize the prevention of VTE has been recognized inWestern countries,
the understanding of the epidemiology of VTE in Asian countries remains limited.
The goal of this population-based observational study is to explore the epidemiol-
ogy and clinical profiles of VTE among cancer patients in Taiwan.METHODS:Using
Taiwan’s National Health Insurance Research Database, we identified newly diag-
nosed cancer patients between 2001 and 2010. Study outcome was defined as a
hospitalization with VTE diagnosis during or after the cancer diagnosis date. To
verify the accuracy of VTE diagnosis, patients must have received subcutaneous or
intravenous anticoagulants, surgical thromboectomy, angioplasty or insertion of
inferior vena cava filter during the VTE hospitalization. The incidence rate of VTE
for the entire study cohort and subgroups of patients categorized by sites of cancer
was estimated. RESULTS: Among 46,061 cancer patients, 555 (2.7 per 1000 patient-
year) patients had VTE admission (438 (78.92%) venous thrombosis, 91 (16.40%)
pulmonary embolism (PE) and 26 (4.68%) with concomitant PE and venous throm-
bosis) during or after the cancer diagnosis date. Sites of cancer with the highest
rates of VTE were myeloma, pancreas, liver, lung, and ovary, with incidence rates
were 5.52, 5.49, 4.67, 4.53, and 4.42 per 1000 patient-year, respectively. Approxi-
mately one-fifth (19.46%, n108) of VTE admission was occurred at the cancer
diagnosis date. Cumulative occurrence of VTE within 1, 3, 6, and 12 months were
26.49%, 40.18%, 49.01%, and 59.28%, respectively. CONCLUSIONS: Although the
incidence of cancer-related VTE among Taiwanese is lower than Caucasians pop-
ulation, it is not rare in specific cancer such asmyeloma, pancreas and liver cancer.
Most VTE occurred within 1 year after cancer diagnosis. Prevention of VTE may be
optimized in higher-risk patients.
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OBJECTIVES: Statin use has been increasing, especially middle-aged and elderly
patients with chronic disease, who use them continuously in Taiwan. Studies con-
ducted in the United States did not report an association between the use of statins
and breast cancer; to the best of our knowledge, no studies of a potential associa-
tion have been conducted in a Chinese population. We analyzed data from the
National Health Insurance Research Database in Taiwan to evaluate the associa-
tion between statin use and breast cancer risk. METHODS: This is a population-
based nested case-control study used data from the Taiwan National Health Insur-
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